QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

GLUE

QT62Monte Rosa Therapeutics, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
18.31
-0.10-0.54%
OverviewShort InterestFilings
GLUEQT62Monte Rosa Therapeutics, Inc.·NASDAQ
OverviewShort InterestFilings
18.31-0.54%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-1.86
Insider Own-
Shs Outstand84.48M
Perf Week7.08%
Market Cap1.20BForward P/E-EPS next Y-1.84Insider Trans-0.03%Shs Float-Perf Month4.15%
Enterprise Value1.08BPEG-EPS next Q-0.37Inst Own-Short Float-Perf Quarter14.01%
Income-129122753.00P/S27.91EPS this Y10.95%Inst Trans-Short Ratio-Perf Half Y-1.88%
Sales42.95MP/B2.31EPS next Y-10.86%ROA-17.65%Short Interest-Perf YTD16.77%
Book/sh6.18P/C-EPS next 5Y-ROE-40.99%52W High25.77 -28.95%Perf Year300.66%
Cash/sh7.88P/FCF-EPS past 3/5Y-ROIC-21.82%52W Low4.12 344.42%Perf 3Y-
Dividend Est.-EV/EBITDA-8.73Sales past 3/5Y-Gross Margin95.28%Volatility4.53% 4.43%Perf 5Y-
Dividend TTM-EV/Sales25.10EPS Y/Y TTM-50.00%Oper. Margin-345.21%ATR (14)1.16Perf 10Y-
Dividend Ex-Date-Quick Ratio9.54Sales Y/Y TTM-43.42%Profit Margin-302.69%RSI (14)51.62Recom2.00
Dividend Gr. 3/5Y-Current Ratio9.54EPS Q/Q-178.95%SMA201.17%Beta1.28Target Price35.00
Payout0.00%Debt/Eq0.07Sales Q/Q-95.29%SMA50-1.96%Rel Volume2.78Prev Close18.41
Employees142LT Debt/Eq0.15EarningsAug 06SMA20015.58%Avg Volume903.42KPrice18.31
IPO DateJun 24, 2021Option/ShortYes / YesEPS/Sales Surpr.-60.71% -63.64%Net Debt/EBITDA0.98Volume2,507,724Change-0.54%
Analyst Ratings
DateActionAnalystRatingTarget
Jan-14-26ReiteratedPiper SandlerOverweight$37
Jan-07-26ReiteratedJefferiesBuy$22 → $31
Jan-07-26ReiteratedWedbushOutperform$26 → $37
Dec-17-25ReiteratedJefferiesBuy$22
Dec-16-25UpgradeWells FargoEqual Weight → Overweight$22
Dec-19-24DowngradeWells FargoOverweight → Equal Weight
Jan-03-23UpgradeWells FargoEqual Weight → Overweight
Latest News
Jun-11-26
Jun-11-2606:49PM
Monte Rosa: Initiating Coverage With A Buy On Degrader Platform PotentialSeekingAlpha
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
Total Revenue4312476
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A288
Gross Profit4111568
Selling, General and Administrative Excl. Other383635
Research and Development154142122
Other Operating Expense-3-8-8
Operating Income-149-54-81
Interest Expense000
Unusual Expense
———
Non-Operating Income (Expense)-17-14-11
Net Income Before Taxes-131-40-70
Income Taxes-2-13
Consolidated Net Income-130-39-73
Net Income From Continuing Operations-130-39-73
Net Income-130-39-73
EPS (Recurring)-1.86-0.46-0.98
EPS (Basic, Before Extraordinaries)-1.86-0.46-0.98
EPS (Diluted)-1.86-0.46-0.98
EBITDA-123-31-62
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio28.1010.50—
Gross Margin95.3592.7489.47
Operating Margin-346.51-43.55-106.58
Net Margin-302.33-31.45-96.05
Shares Outstanding668374
Market Capitalization1,2081,301—
Operating Lease Expense
———
Insider Trading Volume
$20.02$18.07$16.12$14.17$12.22● Close Price0.00K158.67K317.33K476.00K634.67KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Warmuth MarkusPresident & CEOJun 01 '26Sale19.445,466106,253594,538Jun 02 12:00 AM
Townson SharonChief Scientific OfficerMay 29 '26Option Exercise6.1412,00073,680209,290Jun 01 12:00 AM
Townson SharonChief Scientific OfficerMay 29 '26Sale19.876,000119,22067,845Jun 01 12:00 AM
Champoux JenniferChief Operating OfficerMay 27 '26Option Exercise3.984,35017,31464,546May 28 12:00 AM
Champoux JenniferChief Operating OfficerMay 27 '26Sale20.002,17543,50062,371May 28 12:00 AM
Champoux JenniferChief Operating OfficerMay 22 '26Option Exercise3.984,35217,32064,547May 26 12:00 AM
Champoux JenniferChief Operating OfficerMay 22 '26Sale19.002,17641,34462,371May 26 12:00 AM
Manning Anthony M.DirectorMay 21 '26Option Exercise4.1620,00083,20012,100May 22 12:00 AM
Manning Anthony M.DirectorMay 21 '26Sale18.0110,000180,1000May 22 12:00 AM
Warmuth MarkusPresident & CEOMay 01 '26Sale18.925,467103,447600,004May 05 12:00 AM
Warmuth MarkusPresident & CEOApr 14 '26Sale17.648,000141,125605,471Apr 15 12:00 AM
Nickson PhilipChief Business & Legal OfficerApr 09 '26Sale17.695,845103,41355,000Apr 10 12:00 AM
Dunn EdmundPrincipal Accounting OfficerMar 04 '26Sale17.961392,49622,554Mar 05 12:00 AM
Warmuth MarkusPresident & CEOMar 02 '26Sale17.925,46697,974613,471Mar 04 12:00 AM
Dunn EdmundPrincipal Accounting OfficerMar 02 '26Option Exercise13.411,07214,37623,229Mar 02 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR